We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
-$295M
Cap. Flow
-$688M
Cap. Flow %
-3.02%
Top 10 Hldgs %
81.57%
Holding
135
New
6
Increased
16
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$58.8M
2
LEGN icon
Legend Biotech
LEGN
+$52.6M
3
HRTX icon
Heron Therapeutics
HRTX
+$34M
4
JBIO
Jade Biosciences
JBIO
+$32.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.9M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$611M
2
NVTA
Invitae Corporation
NVTA
+$179M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$33.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$32.4M
5
ALT icon
Altimmune
ALT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.26%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$2.81M 0.01%
22,430
– –
TVTX icon
102
Travere Therapeutics
TVTX
$6.19B
$2.73M 0.01%
186,915
– –
RLMD icon
103
Relmada Therapeutics
RLMD
$494M
$2.45M 0.01%
+76,600
New +$2.66M
LOGC
104
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2M 0.01%
451,478
– –
TARA icon
105
Protara Therapeutics
TARA
$228M
$1.95M 0.01%
199,671
– –
INZY
106
DELISTED
Inozyme Pharma
INZY
$1.82M 0.01%
106,999
– –
PASG icon
107
Passage Bio
PASG
$14.3M
$1.55M 0.01%
5,858
-5,910
-50% -$1.83M
AFMD
108
DELISTED
Affimed
AFMD
$1.4M 0.01%
16,461
– –
OYST
109
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.06M ﹤0.01%
61,424
– –
CYPH
110
Cypherpunk Technologies Inc
CYPH
$153M
$918K ﹤0.01%
55,971
– –
BLCM
111
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$822K ﹤0.01%
249,123
– –
KZR
112
DELISTED
Kezar Life Sciences
KZR
$758K ﹤0.01%
13,968
– –
KRRO icon
113
Korro Bio
KRRO
$194M
$553K ﹤0.01%
1,111
– –
SYRS
114
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$357K ﹤0.01%
6,550
-62,467
-91% -$3.7M
AUTL
115
Autolus Therapeutics
AUTL
$641M
– –
-461,726
Closed -$2.65M
GLMD icon
116
Galmed Pharmaceuticals
GLMD
$4.48M
– –
-128
Closed -$634K
LKFT
117
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
– –
-11,180
Closed -$862K
GNFT
118
DELISTED
Genfit
GNFT
– –
-14,720
Closed -$68K
IFRX icon
119
InflaRx
IFRX
$309M
– –
-138,040
Closed -$538K
SGMO
120
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-429,063
Closed -$5.38M
SRPT icon
121
Sarepta Therapeutics
SRPT
$1.98B
– –
-58,700
Closed -$4.38M
VKTX icon
122
Viking Therapeutics
VKTX
$3.95B
– –
-363,980
Closed -$2.3M
XNCR icon
123
Xencor
XNCR
$2.07B
– –
-369,370
Closed -$15.9M
ACGN
124
DELISTED
Aceragen Inc
ACGN
– –
-120,543
Closed -$2.66M
MTEM
125
DELISTED
Molecular Templates, Inc.
MTEM
– –
-8,922
Closed -$1.69M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2021 Portfolio in Review

As of Q2 2021, Julian Baker held 135 positions worth $22.8B, down 1.3% from $23.1B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker withdrew a net $688M in Q2 2021, closing 15 positions and reducing 10 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $611M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Julian Baker opened a new position in Verve Therapeutics worth $85.3M.

  • Julian Baker's largest Q2 2021 buy was Verve Therapeutics: 1,416,530 shares worth $85.3M.
  • Julian Baker added most to Legend Biotech in Q2 2021, an estimated $52.6M increase.
  • Julian Baker's biggest Q2 2021 reduction was Invitae Corporation, cutting an estimated $179M.
  • Julian Baker fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $611M.
  • Julian Baker's ten largest holdings make up 82% of its $22.8B portfolio in Q2 2021.
  • Julian Baker opened 6 new positions and closed 15 in Q2 2021.
  • Julian Baker's portfolio value fell 1.3% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.